INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 36 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $129,000 | -93.6% | 186,000 | -93.3% | 0.00% | -100.0% |
| Q2 2020 | $2,005,000 | -70.4% | 2,768,000 | -45.6% | 0.00% | -50.0% |
| Q4 2019 | $6,773,000 | +30.3% | 5,088,000 | -11.7% | 0.00% | +33.3% |
| Q3 2019 | $5,198,000 | +38.1% | 5,763,000 | +52.1% | 0.00% | +50.0% |
| Q2 2019 | $3,765,000 | – | 3,790,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Context Capital Management, LLC | 2,500,000 | $2,486,000 | 1.44% |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 20,000,000 | $19,894,000 | 1.32% |
| SSI INVESTMENT MANAGEMENT LLC | 6,154,000 | $6,089,000 | 0.45% |
| CSS LLC/IL | 7,750,000 | $7,713,000 | 0.44% |
| Senvest Management, LLC | 5,000,000 | $4,998,000 | 0.44% |
| Antara Capital LP | 2,000,000 | $1,989,000 | 0.43% |
| LINDEN ADVISORS LP | 28,527,000 | $28,380,000 | 0.43% |
| Graham Capital Management, L.P. | 10,650,000 | $10,579,000 | 0.31% |
| WOLVERINE ASSET MANAGEMENT LLC | 19,000,000 | $18,904,000 | 0.25% |
| Polar Asset Management Partners Inc. | 10,000,000 | $9,957,000 | 0.18% |